Overview
Case Challenges in Patients With EGFR-Mutant NSCLC
In the Driver’s Seat With EGFR: Application of Mutation Testing to Treatment Selection for NSCLC
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This activity offers a case challenge of two patients with EGFR-mutant NSCLC, through which learners apply knowledge from the molecular testing guidelines and evidence from clinical trials as presented in the related activity, Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC. Learners work through patient cases during which they are questioned about how they would proceed at different clinical decision points. Expert clinical commentary includes recommendations and evidence for next steps.
This activity is intended for oncologists and pathologists, and the multidisciplinary care team who care for/manage patients with EGFR-mutant NSCLC.
With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a dual/multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches. In this case challenge activity, clinicians apply their knowledge of EGFR testing and clinical trial data to a step-by-step approach to decision making to guide treatment selection for real-world patients with EGFR-mutant NSCLC.
Upon completion of this activity, participants will be able to:
• Explain best practices for EGFR mutation testing in NSCLC
• Apply current evidence for selection of EGFR TKI therapy across patients with diverse EGFR mutations
• Discuss evidence supporting a role of TP53 in the prognosis of NSCLC and response to therapy
• Interpret recent clinical trial data of therapies for EGFR-mutant NSCLC
• Explain best practices for EGFR mutation testing in NSCLC
• Apply current evidence for selection of EGFR TKI therapy across patients with diverse EGFR mutations
• Discuss evidence supporting a role of TP53 in the prognosis of NSCLC and response to therapy
• Interpret recent clinical trial data of therapies for EGFR-mutant NSCLC
This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly.
Justin Gainor, MD
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Justin Gainor, MD
Consultant/Honorarium: Ariad/Takeda, AstraZeneca, Blueprint, Bristol-Myers Squibb, Genentech, Gilead, GlydeBio, Loxo/Lilly, Merck, Moderna, Oncorus, Pfizer, Novartis, Regeneron
Research Support: Ariad/Takeda, Genentech/Roche, Novartis
Research Support (Institutional): Adaptimmune, Alexo, Array Biopharma, Blueprint, Bristol-Myers Squibb, Jounce, Merck, Moderna, Novartis, Tesaro
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
ABPath MOC credit will be submitted on the first day of each month.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .50 MOC points in the American Board of Pathology’s (ABPath) Maintenance of Certification (MOC) program. This activity offers the following types of credit: Lifelong Learning (Part II).
By providing your ABPath Diplomate number, you consent to have ACHL submit your participation in this activity to the ABPath through the ACCME PARS system.
